Evidence map›Paper›PMID 24172897›Full record

ArticleNature2013

Staphylococcus δ-toxin induces allergic skin disease by activating mast cells.

Yuumi Nakamura, Jon Oscherwitz, Kemp B Cease, Susana M Chan, Raul Muñoz-Planillo, Mizuho Hasegawa, Amer E Villaruz, Gordon Y C Cheung, Martin J McGavin, Jeffrey B Travers and 3 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Nature, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03052348 (A Multicentre Study Evaluating the Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Standard of Care in the Treatment of Severe Atopic Dermatitis, a Phase II Randomized, Clinical Trial), which is not on this map. Cited by 294 papers.

0numbers the graph read from it
0cells of the map it votes in
294citing papers in PubMed
34.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03052348 naunknown statusnot on this mapstarted 2017, after this paper: background citation

A Multicentre Study Evaluating the Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Standard of Care in the Treatment of Severe Atopic Dermatitis, a Phase II Randomized, Clinical Trial

TypeinterventionalSponsorRed Cross War Memorial Childrens HospitalRan2017 to 2018Enrolled78ConditionsSevere Atopic DermatitisArmsPolyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%, Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%
3 · Its place in the literature

Who cites it

294 citing papers in PubMed, 533 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Berberine Inhibits Eczematous SkinInternational journal of molecular sciences · 2026
    Article
  9. Article
  10. Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Whole genome sequences of novelMicrobiology resource announcements · 2026
    Article
  16. Dysbiosis in the Pathogenesis of Atopic Dermatitis.The Journal of dermatology · 2026
    Review
  17. Article
  18. Microbiome dysbiosis and therapeutic restoration in atopic dermatitis.Frontiers in cellular and infection microbiology · 2026
    Review
  19. Article
  20. Review

234 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Yuumi NakamuraDepartment of Pathology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.
Jon Oscherwitz
Kemp B Cease
Susana M Chan
Raul Muñoz-Planillo
Mizuho Hasegawa
Amer E Villaruz
Gordon Y C Cheung
Martin J McGavin
Jeffrey B Travers
Michael Otto
Naohiro Inohara
Gabriel Núñez
University of Michigan–Ann Arbor · USNational Institutes of Health · USVA Ann Arbor Healthcare System · USIndiana University – Purdue University Indianapolis · USNational Institute of Allergy and Infectious Diseases · USWestern University · CA

Funding

Staphylococcal pathogenesisZIAAI000904 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI OTTO, MICHAEL · 2009 to 2025
$22.6M
Platelet Activating Factor and Epidermic CytotoxicityR01HL062996 · NHLBI · WRIGHT STATE UNIVERSITY · PI TRAVERS, JEFFREY B. · 1999 to 2023
$7.2M
Role of Mast Cells in NLRP3-Mediated Skin InflammationR01AR059688 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NUNEZ, GABRIEL · 2010 to 2014
$1.7M
Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureusI01BX000429 · VA · VETERANS HEALTH ADMINISTRATION · PI CEASE, KEMP BAILEY · 2011 to 2014
–
BLRD VA I01 BX000429Intramural NIH HHSNHLBI NIH HHS R01 HL062996NHLBI NIH HHS R01HL062996NIAMS NIH HHS R01 AR059688NIAMS NIH HHS R01AR059688
6 · The paper itself

Abstract

Atopic dermatitis is a chronic inflammatory skin disease that affects 15-30% of children and approximately 5% of adults in industrialized countries. Although the pathogenesis of atopic dermatitis is not fully understood, the disease is mediated by an abnormal immunoglobulin-E immune response in the setting of skin barrier dysfunction. Mast cells contribute to immunoglobulin-E-mediated allergic disorders including atopic dermatitis. Upon activation, mast cells release their membrane-bound cytosolic granules leading to the release of several molecules that are important in the pathogenesis of atopic dermatitis and host defence. More than 90% of patients with atopic dermatitis are colonized with Staphylococcus aureus in the lesional skin whereas most healthy individuals do not harbour the pathogen. Several staphylococcal exotoxins can act as superantigens and/or antigens in models of atopic dermatitis. However, the role of these staphylococcal exotoxins in disease pathogenesis remains unclear. Here we report that culture supernatants of S. aureus contain potent mast-cell degranulation activity. Biochemical analysis identified δ-toxin as the mast cell degranulation-inducing factor produced by S. aureus. Mast cell degranulation induced by δ-toxin depended on phosphoinositide 3-kinase and calcium (Ca(2+)) influx; however, unlike that mediated by immunoglobulin-E crosslinking, it did not require the spleen tyrosine kinase. In addition, immunoglobulin-E enhanced δ-toxin-induced mast cell degranulation in the absence of antigen. Furthermore, S. aureus isolates recovered from patients with atopic dermatitis produced large amounts of δ-toxin. Skin colonization with S. aureus, but not a mutant deficient in δ-toxin, promoted immunoglobulin-E and interleukin-4 production, as well as inflammatory skin disease. Furthermore, enhancement of immunoglobulin-E production and dermatitis by δ-toxin was abrogated in Kit(W-sh/W-sh) mast-cell-deficient mice and restored by mast cell reconstitution. These studies identify δ-toxin as a potent inducer of mast cell degranulation and suggest a mechanistic link between S. aureus colonization and allergic skin disease.

Indexed as

Cell DegranulationAnimalsBacterial ToxinsCalcium SignalingCulture Media, ConditionedDermatitis, AtopicFemaleImmunoglobulin EInflammationInterleukin-4Intracellular Signaling Peptides and ProteinsMaleMast CellsMicePhosphatidylinositol 3-KinasesProtein-Tyrosine KinasesBacterial ToxinsCulture Media, ConditionedImmunoglobulin EInterleukin-4Intracellular Signaling Peptides and ProteinsPhosphatidylinositol 3-KinasesProtein-Tyrosine KinasesProto-Oncogene Proteins c-kitstaphylococcal delta toxinSyk KinaseSyk protein, mouse

Identifiers

PMID24172897
PMCPMC4090780
OpenAlexW1972791698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.